Effectiveness of bedaquiline-containing regimens in multidrug-resistant tuberculosis: systematic review and meta-analysis

Authors

Keywords:

antitubercular agents; meta-analysis; treatment expectations; tuberculosis, multidrug-resistant; systematic review

Abstract

Introduction: Tuberculosis control is significantly hindered by the emergence of strains resistant to isoniazid and rifampicin, a condition defined as multidrug-resistant tuberculosis. In response to this challenge, bedaquiline is integrated into all-oral regimens with superior tolerance and patient adherence.

Objective: To determine the effectiveness of bedaquiline-containing therapeutic regimens in adult patients with multidrug-resistant tuberculosis.

Methods: A systematic review was conducted of articles published on PubMed, ScienceDirect, SciElo, LILACS, Europe PMC, Biomed Central and Global Index Medicus between 2020-2025. Clinical studies, comparative studies, multicenter studies, observational studies, and randomized controlled trials involving adults diagnosed with multidrug-resistant and rifampicin-resistant tuberculosis treated with bedaquiline. Primary outcomes were treatment success and mortality; secondary were QT interval prolongation, hepatotoxicity, neuropathy, nephrotoxicity and ototoxicity. Risk ratios were pooled through a meta-analysis, and subgroup analyses were performed to identify sources of heterogeneity.

Results: Data from 10 studies involving 6,521 patients were pooled and 2,393 were treated with bedaquiline. Bedaquiline-containing regimens significantly improved treatment success (RR = 1.25; 95% CI: 1.17–1.35; p < 0.001). Mortality was reduced (RR = 0.71; 95% CI: 0.58-0.88; p = 0.002), although this effect was driven by the largest study. Subgroup analyses confirmed the superiority of bedaquiline over injectable agents, showing higher success rates (RR = 1.29; 95% CI: 1.21–1.37; p < 0.001).

Conclusions: Bedaquiline-containing regimens suggest significant improvement on treatment outcomes compared to conventional regimens. However, further evidence is required to confirm the impact on mortality.

Downloads

Download data is not yet available.

Author Biographies

Yoander Napoles-Zaldivar, Medical Sciences University of Holguin. General Hospital Gustavo Aldereguia Lima

Especialista de 1er Grado en Medicina Interna. Profesor Asistente. Investigador Agregado. Diplomado en Educación Médica y Pase de Visita Hospitalario. Doctorando en Ciencias Biomédicas Clínico-Quirúrgicas

Ivonne Maria Nodarse-Palacios, Medical Sciences University of Holguin. General Hospital Dr. Gustavo Aldereguia Lima. Holguin, Cuba.

Internal Medicine Specialist 

Edilio Silva-Velasco, Medical Sciences University of Holguin. General Hospital "Vladimir Ilich Lenin". Holguin, Cuba.

Internal Medicine Specialist

Juan Carlos Baster-Moro, Medical Sciences University of Holguin. Hygiene, Epidemiology and Microbiology Provincial Center. Holguin, Cuba.

General Medicine Specialist

Luis Anibal Alonso-Betancourt, University of Holguin. Holguin, Cuba

PhD in Pedagogical Sciences

References

1. Switzerland. World Health Organization. Global tuberculosis report 2025 [Internet]. Switzerland, Geneva; 2025. [acceso: 17/04/2026]. Disponible en: https://iris.who.int/server/api/core/bitstreams/e97dd6f4-b567-4396-8680-717bac6869a9/content

2. Falzon D, Schünemann HJ, Harausz E, González-Angulo L, Lienhardt C, Jaramillo E, et al. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update [Internet]. Eur Respir J. 2017; 49(3):1602308. DOI: 10.1183/13993003.02308-2016

3. Ngoc NB, Vu Dinh H, Thuy NT, Quang DV, Huyen CTT, Hoa NM, et al. Active surveillance for adverse events in patients on longer treatment regimens for multidrug-resistant tuberculosis in Viet Nam [Internet]. PLOS ONE. 2021;16(9):e0255357. DOI: 10.1371/journal.pone.0255357

4. Seung KJ, Keshavjee S, Rich ML. Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis [Internet]. Cold Spring Harb Perspect Med. 2015;5(9):a017863. DOI: 10.1101/cshperspect.a017863

5. World Health Organization. Rapid communication: key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB) [Internet]. Geneva: WHO; 2018. [acceso: 17/04/2026]. Disponible en: https://www.who.int/publications/i/item/WHO-CDS-TB-2018.18

6. Al Omar MFS, Alchikhsuliman IEM, Awad SM, Rajab N, Alawi YM, Ibrahim LYM, et al. Hepatic Safety of Bedaquiline, Delamanid, and Pretomanid: A Systematic Review and Meta-analysis [Internet]. Int J Mycobacteriology. 2025;14(4):309. DOI: 10.4103/ijmy.ijmy_97_25

7. Page M, McKenzie J, Bossuyt P, Boutron I, Hoffann T, Mulrow C, et al. Declaración PRISMA 2020: una guía actualizada para la publicación de revisiones sistemáticas [Internet]. Rev Esp Cardiol. 2021;74(9):790-9. DOI: https://doi.org/10.1016/j.recesp.2021.06.016

8. Nápoles-Zaldivar Y, Nodarse-Palacios IM. Systematic review and meta-analysis of effectiveness of bedaquiline-containing regimens in multidrug-resistant tuberculosis [Internet]. PROSPERO. 2026. [acceso:24/04/2026]. Disponible en: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261354749

9. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials [Internet]. BMJ. 2019;l4898. DOI: 10.1136/bmj.l4898

10. ROBINS-I V2 tool [Internet]. Risk of bias tool; 2022. [acceso: 04/04/2026]. Disponible en: https://www.riskofbias.info/welcome/robins-i-v2

11. McGuinness LA, Higgins JPT. Risk‐of‐bias VISualization (robvis): An R package and Shiny web app for visualizing risk‐of‐bias assessments [Internet]. Res Synth Methods. 2021;12(1):55-61. DOI: 10.1002/jrsm.1411

12. GRADEpro GDT: GRADEpro Guideline Development Tool [Software]. McMaster University and Evidence Prime, 2023. [acceso: 29/05/2026]. Disponible en: https://www.gradepro.org

13. Kempker RR, Mikiashvili L, Zhao Y, Benkeser D, Barbakadze K, Bablishvili N, et al. Clinical Outcomes Among Patients With Drug-resistant Tuberculosis Receiving Bedaquiline- or Delamanid-Containing Regimens [Internet]. Clin Infect Dis Off Publ Infect Dis Soc Am. United States; 2020;71(9):2336-44. DOI: 10.1093/cid/ciz1107

14. Pai H, Ndjeka N, Mbuagbaw L, Kaniga K, Birmingham E, Mao G, et al. Bedaquiline safety, efficacy, utilization and emergence of resistance following treatment of multidrug-resistant tuberculosis patients in South Africa: a retrospective cohort analysis [Internet]. BMC Infect Dis. 2022;22(1):870. DOI: 10.1186/s12879-022-07861-x

15. Zhang S-J, Yang Y, Sun W-W, Zhang Z-S, Xiao H-P, Li Y-P, et al. Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR/MDR/XDR-tuberculosis: a retrospective cohort study in East China [Internet]. BMC Infect Dis. 2022;22(1):715. DOI: 10.1186/s12879-022-07693-9

16. Esmail A, Oelofse S, Lombard C, Perumal R, Mbuthini L, Goolam Mahomed A, et al. An All-Oral 6-Month Regimen for Multidrug-Resistant Tuberculosis: A Multicenter, Randomized Controlled Clinical Trial (the NExT Study) [Internet]. Am J Respir Crit Care Med. England; 2022;205(10):1214-27. DOI: 10.1164/rccm.202107-1779OC

17. Fu L, Zhang X, Xiong J, Sun F, Weng T, Li Y, et al. Selecting an appropriate all-oral short-course regimen for patients with multidrug-resistant or pre-extensive drug-resistant tuberculosis in China: A multicenter prospective cohort study [Internet]. Int J Infect Dis. 2023;135:101-8. DOI: 10.1016/j.ijid.2023.08.001

18. Kim JH, Lee H, Oh I-S, Jeong HE, Bea S, Jang SH, et al. Comparative safety of bedaquiline and delamanid in patients with multidrug resistant tuberculosis: A nationwide retrospective cohort study [Internet]. J Microbiol Immunol Infect. 2023;56(4):842-52. DOI: 10.1016/j.jmii.2023.04.009

19. Afifi M, Amin W, Helal D, Ashmawy R, El-Maradny YA, Khalifa N, et al. Impact of bedaquiline regimen on the treatment success rates of multidrug-resistant tuberculosis patients in Egypt [Internet]. Sci Rep. 2024;14(1):16247. DOI: 10.1038/s41598-024-65063-8

20. Santos AP, Benace CJJ, de Medeiros Leung JA, Kritski AL, de Queiroz Mello FC. Bedaquiline versus injectable containing regimens for rifampicin-resistant and multidrug-resistant tuberculosis in a reference center in Brazil - a real-world evidence study using a retrospective design [Internet]. BMC Infect Dis. England; 2024;24(1):1112. DOI: 10.1186/s12879-024-09993-8

21. Jing W, Wang Q, Wang J, Ma L, Huang M, Wang J, et al. New All-Oral Short-term Regimen for Multidrug-Resistant Tuberculosis: A Semi-randomized Controlled Trial Conducted in China [Internet]. Open Forum Infect Dis. 2025;12(2):ofaf020. DOI: 10.1093/ofid/ofaf020

22. Mvungi HC, Mbelele PM, Msaji KS, Mpagama SG, Semvua HH. Comparative Treatment Outcomes of Shorter Regimen in Modified All Oral Regimen with Injectable in Patients Treated for Rifampicin-resistant/Multidrug-resistant Tuberculosis in Tanzania [Internet]. Int J Mycobacteriology. 2025;14(4):340-6. DOI: 10.4103/ijmy.ijmy_98_25

23. Saukkonen JJ, Duarte R, Munsiff SS, Winston CA, Mammen MJ, Abubakar I, et al. Updates on the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis: An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline [Internet]. Am J Respir Crit Care Med. 2025;211(1):15-33. DOI: 10.1164/rccm.202410-2096ST

24. Fekadu G, Tolossa T, Bekele F, Chen X, He Y, Yu J, et al. Impact of all-oral bedaquiline-based shorter regimens in the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis [Internet]. BMJ Glob Health. 2025;10(4):e018220. DOI: 10.1136/bmjgh-2024-018220

25. Bisson GP, Bastos M, Campbell JR, Bang D, Brust JC, Isaakidis P, et al. Mortality in adults with multidrug-resistant tuberculosis and HIV by antiretroviral therapy and tuberculosis drug use: an individual patient data meta-analysis [Internet]. Lancet. 2020;396(10248):402-11. DOI: 10.1016/S0140-6736(20)31316-7

26. Lan Z, Ahmad N, Baghaei P, Barkane L, Benedetti A, Brode SK, et al. Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis [Internet]. Lancet Respir Med. 2020;8(4):383-94. DOI: 10.1016/S2213-2600(20)30047-3

27. Nyang’wa B-T, Berry C, Kazounis E, Motta I, Parpieva N, Tigay Z, et al. A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis [Internet]. N Engl J Med. 2022;387(25):2331-43. DOI: 10.1056/NEJMoa2117166

28. Nahid P, Mase SR, Migliori GB, Sotgiu G, Bothamley GH, Brozek JL, et al. Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline [Internet]. Am J Respir Crit Care Med. 2019;200(10):e93-142. DOI: 10.1164/rccm.201909-1874ST

29. Hasan T, Medcalf E, Nyang’wa B-T, Egizi E, Berry C, Dodd M, et al. The Safety and Tolerability of Linezolid in Novel Short-Course Regimens Containing Bedaquiline, Pretomanid, and Linezolid to Treat Rifampicin-Resistant Tuberculosis: An Individual Patient Data Meta-analysis [Internet]. Clin Infect Dis. 2023;78(3):730-41. DOI: 10.1093/cid/ciad653

30. Bernal O, Lopez R, Montoro E, Avedillo P, Westby K, Ghidinelli M. Introduction and scaling up of new drugs for drug-resistant TB: experiences from the Americas [Internet]. Int J Tuberc Lung Dis. 2020;24(10):1058-62. DOI: 10.5588/ijtld.20.0111

31. Global Drug Facility. Medicines Catalog [Internet]. Geneva: Global Drug Facility; 2026. [acceso: 28/05/2026]. Disponible en: https://www.stoptb.org/sites/default/files/documents/GDF_Medicines_Catalog.pdf

32. Ministerio de Salud Pública. Resolución Ministerial 277/2014. Programa Nacional de Control de la Tuberculosis. Manual de Normas y Procedimientos [Internet]. La Habana: Editorial Ciencias Médicas; 2014 [acceso: 28/05/2026]. Disponible en http://www.sld.cu/galerias/pdf/sitios/tuberculosis/programa_2015.pdf

33. Dirección de Registros Médicos y Estadísticas de Salud. Anuario Estadístico de Salud 2024 [Internet]. La Habana: Editorial Ciencias Médicas; 2025 [acceso: 28/05/2026]. Informe Nro.: 53. Disponible en: https://temas.sld.cu/estadisticassalud/publicaciones-2/anuario-estadistico-de-salud/

Published

2026-11-16

How to Cite

1.
Napoles-Zaldivar Y, Nodarse-Palacios IM, Silva-Velasco E, Baster-Moro JC, Alonso-Betancourt LA. Effectiveness of bedaquiline-containing regimens in multidrug-resistant tuberculosis: systematic review and meta-analysis. Rev. cuba. med. mil [Internet]. 2026 Nov. 16 [cited 2026 Nov. 17];55(4):e026077592. Available from: https://revmedmilitar.sld.cu/index.php/mil/article/view/77592